(Q45856608)

17 December 2017

title

Summary of a workshop on potency and dosage of von Willebrand factor concentrates (English)

1 reference

17 December 2017

0 references

A C Chang

1

1 reference

17 December 2017

M E Rick

series ordinal

2

1 reference

17 December 2017

L Ross Pierce

series ordinal

3

1 reference

17 December 2017

M J Weinstein

series ordinal

4

1 reference

17 December 2017

language of work or name

1 reference

1 January 1998

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

4 Suppl 3

1 reference

17 December 2017

page(s)

1-6

1 reference

17 December 2017

Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant agains

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP--a survey of European physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

The determination of von Willebrand factor activity by collagen binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

In vitro evaluation of the haemostatic value of the LFB-von Willebrand factor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

The effect of von Willebrand factor on activation of factor VIII by factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.0040S3001.X

10.1046/J.1365-2516.1998.0040S3001.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

10028311

1 reference

17 December 2017